A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 20 Jan 2019 Planned End Date changed from 17 Jun 2019 to 14 May 2019.
- 20 Jan 2019 Planned primary completion date changed from 17 Jun 2019 to 14 May 2019.
- 21 Nov 2018 Status changed from recruiting to active, no longer recruiting.